Heron Therapeutics (HRTX) Stock Forecast & Price Target

Heron Therapeutics is supported by a credible commercialization base in APONVIE, SUSTOL, ZYNRELEF, and CINVANTI, with ZYNRELEF emerging as the main driver of upside as IGNITE 2.0 expanded targeted-account unit volume from about 9,000 units to more than 19,000 units by 4Q25, a 111% increase. The broadened IGNITE footprint to 3,109 accounts, roughly 90% alignment with CrossLink across targeted accounts, and planned salesforce expansion suggest stronger coverage and pull-through, while the prefilled syringe and stability work position the franchise for a better long-term adoption curve. Although the 6/1/26 Cinvanti patent ruling creates a generic overhang, the company’s strategic options, potential fit with Azurity, and strong clinical results from Exparel reinforce the view that execution in 2026 can still unlock meaningful value.

Heron Therapeutics is viewed negatively because its revenue base is overly dependent on CINVANTI, which generated $42.3M of $72.4M total revenue in 1H26, while the rest of the portfolio produced only about $30.0M and has not yet proven able to offset erosion. The June 2026 adverse patent ruling on CINVANTI, combined with uncertainty around generic entry, has already forced management to withdraw $173–183M revenue and $10–20M Adjusted EBITDA guidance, pause planned 2H26 sales-force expansion, and tighten spending. With about $142.7M of debt at June 30 and slower-than-expected ZYNRELEF adoption, the company lacks visibility into cash generation, liquidity, and whether Acute Care can scale fast enough to support the business independently.